| irinotecan / Generic mfg. |
NCT00003055: Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer |
|
|
| Completed | 2 | | US | cisplatin, irinotecan hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 04/01 | 04/01 | | |
NCT00030862: Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus |
|
|
| Completed | 2 | | US | cisplatin, irinotecan hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer | 12/03 | 12/03 | | |
NCT00003137: Irinotecan in Treating Patients With Advanced Cancer of the Stomach |
|
|
| Completed | 2 | 70 | US, Canada | irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 07/04 | 07/04 | | |
NCT00004235: Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach |
|
|
| Completed | 2 | 47 | US, Canada | docetaxel, irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 08/04 | 08/04 | | |
NCT00137852: Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer |
|
|
| Completed | 2 | 35 | US | Cisplatin, Irinotecan, CPT-11, Celecoxib, Radiation Therapy, Esophagectomy | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Pharmacia | Esophageal Cancer | 08/04 | 09/17 | | |
NCT00165464: Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer |
|
|
| Completed | 2 | 54 | US | Taxotere, Cisplatin, Irinotecan | Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Aventis Pharmaceuticals | Esophageal Cancer, Gastric Cancer, GE Junction Cancer | 03/05 | 04/09 | | |
NCT00183807: A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer |
|
|
| Terminated | 2 | 6 | US | irinotecan, cisplatin, celecoxib | University of Southern California, Pfizer | Esophageal Cancer | 02/06 | 03/08 | | |
NCT00012363: S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus |
|
|
| Completed | 2 | 61 | US | gemcitabine hydrochloride, Gemzar (NSC-613327), irinotecan hydrochloride, CPT-11 (NSC-616348) | Southwest Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 04/06 | 04/06 | | |
NCT00318903: Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer |
|
|
| Completed | 2 | 25 | US | Irinotecan (drug), Camptosar, Taxotere (drug), Docetaxel, Radiotherapy (procedure), Esophagectomy (procedure) | University of Alabama at Birmingham, Aventis Pharmaceuticals, Pharmacia and Upjohn | Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus | | 04/06 | | |
NCT00201747: Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer |
|
|
| Completed | 2 | 80 | US | CPT-11, Mitomycin C | Ohio State University Comprehensive Cancer Center, Pharmacia and Upjohn | Esophageal Cancer, Esophagus Cancer, Cancer of Stomach, Stomach Cancer | 10/06 | 02/10 | | |
NCT00520091: Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer |
|
|
| Completed | 2 | 14 | US | CPT- 11, Irinotecan, Cisplatin, Cis-diammine-dichloro-platinum, Celecoxib, Radiation, Surgery | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer | 11/06 | 09/10 | | |
NCT00256269: Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma |
|
|
| Terminated | 2 | 4 | US | Oxaliplatin, Irinotecan | University of California, Irvine, Sanofi | Esophageal Cancer, Gastroesophageal Cancer | 02/07 | 02/07 | | |
NCT00215995: Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas |
|
|
| Completed | 2 | 21 | US | Cisplatin, Platinol, Platinol-AQ, Irinotecan, Camptosar, ZD 1839, Iressa | H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca | Esophageal Cancer, Gastric Cancer | 05/07 | 05/07 | | |
NCT00084604: Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Completed | 2 | 47 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, cisplatin, CACP, CDDP, CPDD, DDP, computed tomography, tomography, computed, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer | 10/07 | | | |
NCT00165490: Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer |
|
|
| Completed | 2 | 19 | US | Cetuximab, Cisplatin, Irinotecan, Radiation therapy, Surgery | Dana-Farber Cancer Institute, Brigham and Women's Hospital | Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus | 11/07 | 11/14 | | |
NCT00084617: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
|
|
| Completed | 2 | 39 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer | 10/08 | 12/08 | | |
NCT00394433: Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer |
|
|
| Completed | 2 | 38 | US | Bevacizumab, Avastin, Docetaxel, Taxotere, Docefrez, Cisplatin, Platinol-AQ, Platinol, Irinotecan, Camptosar | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc. | Esophageal Cancer, Stomach Cancer | 11/08 | 10/16 | | |
NCT00033657: Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer |
|
|
| Completed | 2 | 97 | US | cisplatin, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875, irinotecan hydrochloride, Camptothecin-11, CPT-11, Camptosar, paclitaxel, Taxol, NSC 125973, conventional surgery, radiation therapy | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 09/09 | 10/09 | | |
NCT00109850: S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer |
|
|
| Terminated | 2 | 22 | US | cetuximab, Erbitux, cisplatin, Platinol, irinotecan hydrochloride, CPT-11, radiation therapy, RT, TRT | Southwest Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer | 09/09 | 05/12 | | |
|
NCT00590031: Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. |
|
|
| Completed | 2 | 61 | US | Cisplatin, Irinotecan, External Beam Radiation Therapy | Memorial Sloan Kettering Cancer Center | Esophageal Carcinoma | 12/09 | 12/09 | | |
NCT00397904: Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin |
|
|
| Completed | 2 | 16 | US | cetuximab, cisplatin, irinotecan hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 09/10 | 09/10 | | |
NCT00848783: Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers |
|
|
| Terminated | 2 | 8 | US | Irinotecan, CPT-11, Cisplatin, Surgery, Floxuridine, FUDR, Capecitabine, Xeloda | NYU Langone Health | Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer | 08/11 | 09/12 | | |
NCT00991952: Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 19 | US | alvocidib, FLAVO, flavopiridol, HMR 1275, L-868275, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer | 02/12 | 04/14 | | |
NCT00316862: Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery |
|
|
| Completed | 2 | 82 | US | cisplatin, irinotecan hydrochloride, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer | 12/12 | 10/14 | | |
NCT00183872: Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Completed | 2 | 40 | US | irinotecan, docetaxel | University of Southern California, Sanofi | Gastric Cancer, Esophageal Neoplasms | 10/14 | 10/15 | | |
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma |
|
|
| Completed | 2 | 22 | US | epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery. | Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University | Esophageal Cancer, Gastric Cancer | 02/15 | 02/15 | | |
|
NCT00354679: Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer |
|
|
| Completed | 2 | 34 | US | bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer | 06/15 | 06/15 | | |
|
|
| Completed | 2 | 24 | US | Panitumumab, ABX-EGF, Irinotecan, Camptosar, Campto, CPT-11 | Weijing Sun, MD, FACP, Amgen | Esophageal Cancer | 08/15 | 08/15 | | |
NCT01608464: Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer |
|
|
| Terminated | 2 | 170 | RoW | irinotecan and docetaxel, Irinotecan, Docetaxel, Cisplatin, fluorouracil and concurrent radiation therapy, Cisplatin, 5-FU, Concurrent RT with CDDP and 5-FU | King Faisal Specialist Hospital & Research Center | Carcinoma of Esophagus | 09/15 | 09/15 | | |
NCT00400114: Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer |
|
|
| Completed | 2 | 36 | Canada | Irinotecan, Cisplatin, Radiation, Surgery, sunitinib (Sutent) | University Health Network, Toronto, Pfizer | Esophageal Cancer | 09/16 | 09/16 | | |
NCT00290719: Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery |
|
|
| Terminated | 1/2 | 6 | US | cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy | University of California, San Francisco, National Cancer Institute (NCI) | Esophageal Cancer | 04/08 | 06/08 | | |
